Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Dec;41(12):2749–2753. doi: 10.1128/aac.41.12.2749

Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium.

F Caron 1, H S Gold 1, C B Wennersten 1, M G Farris 1, R C Moellering Jr 1, G M Eliopoulos 1
PMCID: PMC164201  PMID: 9420051

Abstract

RP 59500, a mixture of two semisynthetic streptogramin antibiotics (quinupristin and dalfopristin), is one of a few investigational agents currently in clinical trials with inhibitory activity against multiple-drug-resistant strains of Enterococcus faecium. We evaluated the bactericidal activity of this antimicrobial against 30 recent clinical isolates of vancomycin-resistant E. faecium, including 23 erythromycin-resistant (MIC, >256 microg/ml) and 7 erythromycin-intermediate (MIC, 2 to 4 microg/ml) strains. All isolates were inhibited by RP 59500 at 0.25 to 1.0 microg/ml. The bactericidal activity of RP 59500 was markedly influenced by the erythromycin susceptibility of the strains and by several technical factors, such as inoculum growth phase and time of incubation of counting plates. As determined by time-kill methods, RP 59500 at a concentration of 2 or 8 microg/ml failed to kill erythromycin-resistant organisms under any conditions. Bactericidal activity was observed against all seven erythromycin-intermediate isolates when log-phase inocula were used and the cells were counted after 48 h of incubation (mean reductions in viable bacteria for RP 59500 at concentrations of 2 and 8 microg/ml, 3.45 and 3.50 log10 CFU/ml, respectively), but killing was diminished when the plates were examined at 72 h (mean killing, 3.06 and 2.95 log10, CFU/ml, respectively). No bactericidal activity was observed when stationary-phase cultures were used. On the basis of these data, we expect that bactericidal activity of RP 59500 against the multiple-drug-resistant E. faecium strains currently encountered would be distinctly uncommon.

Full Text

The Full Text of this article is available as a PDF (149.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aumercier M., Bouhallab S., Capmau M. L., Le Goffic F. RP 59500: a proposed mechanism for its bactericidal activity. J Antimicrob Chemother. 1992 Jul;30 (Suppl A):9–14. doi: 10.1093/jac/30.suppl_a.9. [DOI] [PubMed] [Google Scholar]
  2. Bouanchaud D. H. In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin. J Antimicrob Chemother. 1997 May;39 (Suppl A):15–21. doi: 10.1093/jac/39.suppl_1.15. [DOI] [PubMed] [Google Scholar]
  3. Bouanchaud D. H. In-vitro and in-vivo synergic activity and fractional inhibitory concentration (FIC) of the components of a semisynthetic streptogramin, RP 59500. J Antimicrob Chemother. 1992 Jul;30 (Suppl A):95–99. doi: 10.1093/jac/30.suppl_a.95. [DOI] [PubMed] [Google Scholar]
  4. Brumfitt W., Hamilton-Miller J. M., Shah S. In-vitro activity of RP 59500, a new semisynthetic streptogramin antibiotic, against gram-positive bacteria. J Antimicrob Chemother. 1992 Jul;30 (Suppl A):29–37. doi: 10.1093/jac/30.suppl_a.29. [DOI] [PubMed] [Google Scholar]
  5. Collins L. A., Malanoski G. J., Eliopoulos G. M., Wennersten C. B., Ferraro M. J., Moellering R. C., Jr In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother. 1993 Mar;37(3):598–601. doi: 10.1128/aac.37.3.598. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Entenza J. M., Drugeon H., Glauser M. P., Moreillon P. Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500. Antimicrob Agents Chemother. 1995 Jul;39(7):1419–1424. doi: 10.1128/aac.39.7.1419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Etienne S. D., Montay G., Le Liboux A., Frydman A., Garaud J. J. A phase I, double-blind, placebo-controlled study of the tolerance and pharmacokinetic behaviour of RP 59500. J Antimicrob Chemother. 1992 Jul;30 (Suppl A):123–131. doi: 10.1093/jac/30.suppl_a.123. [DOI] [PubMed] [Google Scholar]
  8. Fantin B., Leclercq R., Garry L., Carbon C. Influence of inducible cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics in Enterococcus faecium on activity of quinupristin-dalfopristin in vitro and in rabbits with experimental endocarditis. Antimicrob Agents Chemother. 1997 May;41(5):931–935. doi: 10.1128/aac.41.5.931. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Fantin B., Leclercq R., Merlé Y., Saint-Julien L., Veyrat C., Duval J., Carbon C. Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus. Antimicrob Agents Chemother. 1995 Feb;39(2):400–405. doi: 10.1128/aac.39.2.400. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Fass R. J. In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci. Antimicrob Agents Chemother. 1991 Mar;35(3):553–559. doi: 10.1128/aac.35.3.553. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Freeman C., Robinson A., Cooper B., Mazens-Sullivan M., Quintiliani R., Nightingale C. In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci. Diagn Microbiol Infect Dis. 1995 Jan;21(1):47–50. doi: 10.1016/0732-8893(94)00113-b. [DOI] [PubMed] [Google Scholar]
  12. Fremaux A., Sissia G., Cohen R., Geslin P. In-vitro antibacterial activity of RP 59500, a semisynthetic streptogramin, against Streptococcus pneumoniae. J Antimicrob Chemother. 1992 Jul;30 (Suppl A):19–23. doi: 10.1093/jac/30.suppl_a.19. [DOI] [PubMed] [Google Scholar]
  13. Gold H. S., Unal S., Cercenado E., Thauvin-Eliopoulos C., Eliopoulos G. M., Wennersten C. B., Moellering R. C., Jr A gene conferring resistance to vancomycin but not teicoplanin in isolates of Enterococcus faecalis and Enterococcus faecium demonstrates homology with vanB, vanA, and vanC genes of enterococci. Antimicrob Agents Chemother. 1993 Aug;37(8):1604–1609. doi: 10.1128/aac.37.8.1604. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Goto S., Miyazaki S., Kaneko Y. The in-vitro activity of RP 59500 against gram-positive cocci. J Antimicrob Chemother. 1992 Jul;30 (Suppl A):25–28. doi: 10.1093/jac/30.suppl_a.25. [DOI] [PubMed] [Google Scholar]
  15. Handwerger S., Pucci M. J., Kolokathis A. Vancomycin resistance is encoded on a pheromone response plasmid in Enterococcus faecium 228. Antimicrob Agents Chemother. 1990 Feb;34(2):358–360. doi: 10.1128/aac.34.2.358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Johnson C. C., Slavoski L., Schwartz M., May P., Pitsakis P. G., Shur A. L., Levison M. E. In vitro activity of RP 59500 (quinupristin/dalfopristin) against antibiotic-resistant strains of Streptococcus pneumoniae and enterococci. Diagn Microbiol Infect Dis. 1995 Mar;21(3):169–173. doi: 10.1016/0732-8893(95)00068-l. [DOI] [PubMed] [Google Scholar]
  17. Jones R. N., Sader H. S., Erwin M. E., Anderson S. C. Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group. Diagn Microbiol Infect Dis. 1995 Feb;21(2):85–93. doi: 10.1016/0732-8893(94)00147-o. [DOI] [PubMed] [Google Scholar]
  18. L'Hériteau F., Entenza J. M., Lacassin F., Leport C., Glauser M. P., Moreillon P. RP 59500 prophylaxis of experimental endocarditis due to erythromycin-susceptible and -resistant isogenic pairs of viridans group streptococci. Antimicrob Agents Chemother. 1995 Jul;39(7):1425–1429. doi: 10.1128/aac.39.7.1425. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Leclercq R., Nantas L., Soussy C. J., Duval J. Activity of RP 59500, a new parenteral semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolide-lincosamide-streptogramin antibiotics. J Antimicrob Chemother. 1992 Jul;30 (Suppl A):67–75. doi: 10.1093/jac/30.suppl_a.67. [DOI] [PubMed] [Google Scholar]
  20. Nougayrede A., Berthaud N., Bouanchaud D. H. Post-antibiotic effects of RP 59500 with Staphylococcus aureus. J Antimicrob Chemother. 1992 Jul;30 (Suppl A):101–106. doi: 10.1093/jac/30.suppl_a.101. [DOI] [PubMed] [Google Scholar]
  21. Pankuch G. A., Lichtenberger C., Jacobs M. R., Appelbaum P. C. Antipneumococcal activities of RP 59500 (quinupristin-dalfopristin), penicillin G, erythromycin, and sparfloxacin determined by MIC and rapid time-kill methodologies. Antimicrob Agents Chemother. 1996 Jul;40(7):1653–1656. doi: 10.1128/aac.40.7.1653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Pearson R. D., Steigbigel R. T., Davis H. T., Chapman S. W. Method of reliable determination of minimal lethal antibiotic concentrations. Antimicrob Agents Chemother. 1980 Nov;18(5):699–708. doi: 10.1128/aac.18.5.699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Rende-Fournier R., Leclercq R., Galimand M., Duval J., Courvalin P. Identification of the satA gene encoding a streptogramin A acetyltransferase in Enterococcus faecium BM4145. Antimicrob Agents Chemother. 1993 Oct;37(10):2119–2125. doi: 10.1128/aac.37.10.2119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Soussy C. J., Acar J. F., Cluzel R., Courvalin P., Duval J., Fleurette J., Megraud F., Meyran M., Thabaut A. A collaborative study of the in-vitro sensitivity to RP 59500 of bacteria isolated in seven hospitals in France. J Antimicrob Chemother. 1992 Jul;30 (Suppl A):53–58. doi: 10.1093/jac/30.suppl_a.53. [DOI] [PubMed] [Google Scholar]
  25. Williams J. D., Maskell J. P., Whiley A. C., Sefton A. M. Comparative in-vitro activity of quinupristin/dalfopristin against Enterococcus spp. J Antimicrob Chemother. 1997 May;39 (Suppl A):41–46. doi: 10.1093/jac/39.suppl_1.41. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES